- Report
- February 2024
- 150 Pages
Global
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2024
- 176 Pages
Global
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2024
- 120 Pages
Global
From €4519EUR$4,750USD£3,850GBP
- Report
- April 2024
- 185 Pages
Global
From €4662EUR$4,900USD£3,971GBP
- Report
- June 2024
Global
From €5661EUR$5,950USD£4,822GBP
- Report
- June 2024
Global
From €6184EUR$6,500USD£5,268GBP
- Report
- February 2024
- 143 Pages
Global
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2024
- 181 Pages
Europe
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2024
- 90 Pages
United States
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2024
- 160 Pages
Middle East, Africa
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2024
- 90 Pages
Europe
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2024
- 70 Pages
Latin America
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2024
- 70 Pages
United States
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2024
- 80 Pages
Europe
From €4519EUR$4,750USD£3,850GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2024
- 85 Pages
North America
From €4519EUR$4,750USD£3,850GBP
- Report
- August 2023
- 150 Pages
North America
From €4519EUR$4,750USD£3,850GBP
- Report
- February 2021
- 500 Pages
United States
From €1941EUR$2,040USD£1,653GBP
€2283EUR$2,400USD£1,945GBP
Apidra is a brand of insulin glulisine, a fast-acting insulin analog used to treat diabetes mellitus. It is used to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes. Apidra is a part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat endocrine and metabolic disorders such as diabetes, thyroid disorders, and obesity. These drugs are used to regulate hormones, metabolism, and other body functions.
The Endocrine and Metabolic Disorders Drugs market is a rapidly growing market, driven by the increasing prevalence of diabetes and other endocrine and metabolic disorders. The market is expected to continue to grow in the coming years, driven by the increasing demand for new and improved treatments.
Some of the major companies in the Apidra market include Sanofi, Eli Lilly, Novo Nordisk, Merck, and AstraZeneca. Show Less Read more